Experimental infection and protection against ... - TI Pharma

Introduction 23
20. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced
by the injection of x-irradiated sporozoites of plasmodium berghei. Nature
1967; 216:160-162.
21. Nussenzweig V, Nussenzweig RS. Development of a sporozoite malaria vaccine.
Am J Trop Med Hyg 1986; 35:678-688.
22. Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against
Plasmodium falciparum infection and disease in young African children:
randomised controlled trial. Lancet 2004; 364:1411-1420.
23. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A
malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican
children: single-blind extended follow-up of a randomised controlled trial.
Lancet 2005; 366:2012-2018.
24. Sacarlal J, Aide P, Aponte JJ et al. Long-term safety and efficacy of the
RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009;
200:329-336.
25. Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria
in children 5 to 17 months of age. N Engl J Med 2008; 359:2521-2532.
26. Abdulla S, Oberholzer R, Juma O et al. Safety and immunogenicity of
RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008; 359:2533-2544.
27. Agnandji ST, Lell B, Soulanoudjingar SS et al. First results of phase 3 trial of
RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863-
1875.
28. Luty AJ, Lell B, Schmidt-Ott R et al. Interferon-gamma responses are associated
with resistance to reinfection with Plasmodium falciparum in young African
children. J Infect Dis 1999; 179:980-988.
29. John CC, Tande AJ, Moormann AM et al. Antibodies to pre-erythrocytic
Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J
Infect Dis 2008; 197:519-526.
30. Pichyangkul S, Kum-Arb U, Yongvanitchit K et al. Preclinical evaluation of the
safety and immunogenicity of a vaccine consisting of Plasmodium falciparum
liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently
with the RTS,S/AS01B vaccine in rhesus primates. Infect Immun 2008; 76:229-
238.
31. Cummings JF, Spring MD, Schwenk RJ et al. Recombinant Liver Stage Antigen-1
(LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and
induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental
Plasmodium falciparum infection. Vaccine 2010; 28:5135-5144.
32. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of
plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara
in humans. Nat Med 2003; 9:729-735.
33. Moorthy VS, Imoukhuede EB, Milligan P et al. A randomised, double-blind,
controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection
in Gambian adults. PLoS Med 2004; 1:e33.